A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer
| Autor: | Giuseppe Comella, Anna Maria Baldelli, Vincenzo Catalano, Francesco Graziano, R Casaretti, Roberto Labianca, Stefano Cascinu, Sandro Barni, Luciano Frontini, Giuseppina Catalano |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Neutropenia Paclitaxel Injections Subcutaneous medicine.medical_treatment Leucovorin Phases of clinical research Docetaxel Filgrastim Gastroenterology Drug Administration Schedule Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Infusions Intravenous Fatigue Aged Epirubicin sequential chemotherapy Chemotherapy business.industry gastric cancer Regular Article Middle Aged Antineoplastic Agents Phytogenic Glutathione Thrombocytopenia PELF Regimen Surgery Regimen Treatment Outcome Oncology Fluorouracil Drug Therapy Combination Female Taxoids Cisplatin business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 |
| DOI: | 10.1054/bjoc.2000.1631 |
| Popis: | In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim. Chemotherapy-naive patients with relapsed or metastatic gastric cancer received 8 weekly administrations of chemotherapy with cisplatin 40 mg/m2, fluorouracil 500 mg/m2,epi-doxorubicin 35 mg/m2, 6S-steroisomer of leucovorin 250 mg/m2and glutathione 1.5 g/m2. On the other days filgrastim 5 μg kg–1was administered by subcutanous injection. Subsequently, patients with partial response or stable disease received 3 cycles of docetaxel 100 mg/m2every 3 weeks. 40 patients have been enrolled and they are evaluable for response and toxicity. After the PELF regimen, 3 patients achieved complete response, 13 patients showed partial response, 21 patients had stable disease and 3 patients progressed (40% response rate; 95% CI 25% to 55%). After docetaxel, 9 out 34 patients improved the outcome (26.5%); 7 patients with stable disease achieved partial response and 2 patients with partial response achieved complete response. The overall response rate in the 40 patients was 57.5% (95% CI, 42.5% to 72.5%). The PELF regimen did not cause any grade IV toxicity, the most frequent grade III acute side-effects were thrombocytopenia and vomiting which occurred in the 10% of 320 PELF cycles. Docetaxel caused grade III–IV neutropenia and thrombocytopenia in the 10% and the 19% of cycles respectively. Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy. The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|